Why did Americans report more long COVID brain fog?

Large international study finds uneven cognitive burden

A cross-national analysis of more than 3,100 people living with long COVID revealed a notable discrepancy in brain-related symptoms between the United States and other countries. U.S.-based participants reported far higher rates of cognitive problems often labeled as “brain fog,” including difficulty concentrating, memory lapses, and slowed thinking. The finding does not settle a single cause, but it highlights a clear public‑health signal: cognitive sequelae of SARS‑CoV‑2 infection are widespread and appear to vary by region.

Several kinds of explanations could account for the pattern. Differences in health‑care access and diagnosis mean U.S. patients may be more likely to enter studies or receive a formal long‑COVID label, raising observed rates. Variations in viral exposure, circulating variants, timing and uptake of vaccines, and the prevalence of other chronic conditions that worsen cognitive symptoms could also play roles. Sociodemographic factors—such as socioeconomic stress, occupational exposures, and comorbid mental‑health conditions—affect both risk and reporting of cognitive complaints. Finally, methodological factors, including recruitment strategies and the instruments used to measure cognition, can magnify apparent national differences.

Why this matters

• Patients: Cognitive symptoms can disrupt work, caregiving, and daily living, so higher burden means more people need services.
• Health systems: Clinicians and rehabilitation programs must be prepared for regional surges in demand for cognitive assessment and support.
• Research: Understanding whether the gap is biological, social, or artefactual will determine whether interventions should target biology (e.g., neuroinflammation) or social support and access to care.

It’s still unclear which combination of factors drives the U.S. pattern. The study underlines the need for standardized, representative surveillance of long COVID and for clinical trials that test targeted therapies and rehabilitation approaches for cognitive symptoms.